SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac Hypertrophy
Advanced Science · 2024-03 · 11 (12)
DOI: 10.1002/advs.202305677 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 15.01.2024. Verfasst von Xin Shi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China. Hauptthemen laut MEDLINE: Sumoylation, Heart Failure. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, SINO-GERMAN Mobility Programme, Shanghai Sailing Program.
Abstract (Originalsprache)
Pathological cardiac hypertrophy is the leading cause of heart failure and has an extremely complicated pathogenesis. TEA domain transcription factor 1 (TEAD1) is recognized as an important transcription factor that plays a key regulatory role in cardiovascular disease. This study aimed to explore the role of TEAD1 in cardiac hypertrophy and to clarify the regulatory role of small ubiquitin‐like modifier (SUMO)‐mediated modifications. First, the expression level of TEAD1 in patients with heart failure, mice, and cardiomyocytes is investigated. It is discovered that TEAD1 is modified by SUMO1 during cardiac hypertrophy and that the process of deSUMOylation is regulated by SUMO‐specific protease 1 (SENP1). Lysine 173 is an essential site for TEAD1 SUMOylation, which affects the protein stability, nuclear localization, and DNA‐binding ability of TEAD1 and enhances the interaction between TEAD1 and its transcriptional co‐activator yes‐associated protein 1 in the Hippo pathway. Finally, adeno‐associated virus serotype 9 is used to construct TEAD1 wild‐type and KR mutant mice and demonstrated that the deSUMOylation of TEAD1 markedly exacerbated cardiomyocyte enlargement in vitro and in a mouse model of cardiac hypertrophy. The results provide novel evidence that the SUMOylation of TEAD1 is a promising therapeutic strategy for hypertrophy‐related heart failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
- Department of Cardiovascular Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
- Department of Central Laboratory, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
- Department of Cardiothoracic Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
- General Surgery Department, Shanghai Chest Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai, 200030, China.
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, China.
ORCID-Profile: Xin Shi
Förderung
- National Natural Science Foundation of China
- SINO-GERMAN Mobility Programme
- Shanghai Sailing Program
- Shanghai Science and Technology
Zitieren
APA
Shi, X., Dang, X., Huang, Z., Lu, Y., Tong, H., Liang, F., Zhuang, F., Li, Y., Cai, Z., Huo, H., Jiang, Z., Pan, C., Wang, X., Gu, C., & He, B. (2024). SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac Hypertrophy. Advanced Science, 11(12). https://doi.org/10.1002/advs.202305677
Vancouver
Shi X, Dang X, Huang Z, Lu Y, Tong H, Liang F, et al. SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac Hypertrophy. Advanced Science. 2024;11(12). doi:10.1002/advs.202305677
BibTeX
@article{Shi2024,
author = {Shi, Xin and Dang, Xuening and Huang, Zhenyu and Lu, Yanqiao and Tong, Huan and Liang, Feng and Zhuang, Fei and Li, Yi and Cai, Zhaohua and Huo, Huanhuan and Jiang, Zhaolei and Pan, Changqing and Wang, Xia and Gu, Chang and He, Ben},
title = {SUMOylation of TEAD1 Modulates the Mechanism of Pathological Cardiac Hypertrophy},
journal = {Advanced Science},
year = {2024},
volume = {11},
number = {12},
doi = {10.1002/advs.202305677}
}
EUVIMED